Selegiline for Smoking Cessation - 1

Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.

The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.

Inclusion Criteria:

• Must be at least 18 years of age
• Be in good general health
• Must meet Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for nicotine dependence
• Be currently smoking > 15 cigarettes/day, and have smoked cigarettes for the past 5 years
• Subjects must be motivated to quite smoking
• If female and of child bearing potential, agrees to use birth control and subject
• Subject must be able to understand and provide written informed consent.

Exclusion

Criteria:

• Please contact site for more information